ArticleCardio-oncology (London, England)2026
Intimal sarcomas (ISarc) of the cardiac chambers (CC) of the heart and great vessels (GV): a comprehensive genomic profiling (CGP) study.
Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundISarc of the CC and GV are extremely rare primary tumors of the cardiac chambers (CC), aortic root (AO) and pulmonary artery (PA). These tumors are rarely resectable and are associated with rapid progression and poor clinical outcome. We queried whether CGP could uncover new routes to targeted therapies for this aggressive form of malignancy.
methods27 cases of ISarc were centrally reviewed and required direct association with the intimal surfaces of the CC and GV with supporting routine histologic features and immunohistochemical staining patterns. DNA and RNA extracted from the ISarc cases were both sequenced using a hybrid-capture based CGP to study all classes of genomic alterations (GA) and determine MSI status, TMB level, HRD score, genomic ancestry, cosmic trinucleotide signature (Signature) and germline status. PD-L1 expression was measured by IHC (Dako 22C3 and TPS scoring).
resultsAmong 27 ISarc cases (15 CC, 12 GV—11 pulmonary artery, 1 aortic root), most were high-grade tumors (89% grade 3, 11% grade 2). Median age was 45–46 years across groups. CC ISarc patients were more often female (73% vs 50%; P=0.26). Genomic alterations relevant to targeted therapy included MDM2 (67% CC, 50% GV), PDGFRA (53% CC, 42% GV), CDK4 (60% CC, 33% GV), and KIT (40% CC, 33% GV), though differences were not significant. CDKN2A deletions were more common in GV (67% vs 27%, P=0.055). PIK3CA mutations were significantly more frequent in CC (20% vs 0%, P=0.007); ERBB3 mutations were infrequent and not significant. EUR ancestry was seen in just over 50% of cases. Of four ISarc cases analyzed for mutational signatures, three had MMR and one APOBEC; none were MSI-high. Median TMB was similar (4.3–4.7 mut/Mb), with one CC case >10 mut/Mb. One GV case had germline VHL and KEAP1 mutations. Low PD-L1 expression was found in 1/5 (20%) of tested ISarc cases.
conclusionsCGP of ISarc cases reveals that these tumors do feature a modest number of GA potentially associated with benefit for targeted therapies but low and absent biomarkers predictive of immunotherapy benefit. Further study of ISarc in a setting of rare tumor clinical trials appears warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.